Achondroplasia (ACH) is a common genetic skeletal dysplasia. Its core clinical manifestations include disproportionate short stature, macrocephaly with frontal bossing, midface hypoplasia, and bowed tibia. The incidence ranges from 1 in 15,000 to 1 in 25,000 live births.
Pathogenesis
The onset of achondroplasia is tightly linked to mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. Over 97% of clinical cases stem from a missense mutation (p.G380R) located in the transmembrane domain of FGFR3 on the short arm of chromosome 4. This mutation causes sustained overactivation of FGFR3 receptors, which releases inhibitory signals that block endochondral ossification and ultimately leads to rhizomelic skeletal dysplasia and short stature.
Approximately 98% of ACH patients carry the c.1138G>A variant of FGFR3, while a small subset carries c.1138G>C; both variants result in the Gly380Arg amino acid substitution.
Therapeutic Strategies Under Research
1、Viral Vector Gene Therapy
Normal FGFR3 genes are delivered into patient cells via viral vectors to replace mutated copies and restore physiological bone growth and development. This approach remains in preclinical research and development.
2、mRNA Therapy
Modified mRNA encoding wild-type FGFR3 is introduced into cells to produce functional normal FGFR3 protein.
3、Gene Editing Technology
Precise repair or modification of endogenous mutant FGFR3 genes in patients.
4、RNA Interference (RNAi)
shRNA or siRNA molecules target and degrade mutant FGFR3 mRNA to reduce the production of abnormal FGFR3 protein.
5、Targeted Signaling Inhibition
Antisense oligonucleotides (ASOs) or small-molecule drugs suppress the overactive downstream MAPK signaling cascade triggered by mutant FGFR3.
Research Mouse Models for Achondroplasia
1、FGFR3-Gly380Arg Mice
This strain recapitulates the most prevalent human G380R mutation and faithfully reproduces core pathological phenotypes of human achondroplasia, including marked growth retardation and skeletal malformation during bone development.
2、FGFR3-/- Knockout Mice
This model reveals the native physiological function of FGFR3 as a negative regulator of bone growth; complete knockout leads to excessive skeletal overgrowth.
3、FGFR3 Y367C/+ Mice
The Y367C variant mouse is widely used to investigate the impacts of ACH on craniofacial bone structures such as the mandible.
MingCeler Biotech Supports Gene Therapy R&D
Gene therapy brings new hope for rare disease treatment, yet its development and validation heavily rely on validated animal models. Leveraging our proprietary TurboMice™ technology, MingCeler Biotech has generated multiple rare disease mouse models. TurboMice™ overcomes two major bottlenecks of traditional model generation: long breeding cycles and low success rates for complex strains. The platform enables editing of nearly any target gene locus and generates fully homozygous gene-edited mice directly from embryonic stem cells in as little as 2 months.
MingCeler Biotech provides custom ACH mouse models including FGFR3-Gly380Arg, FGFR3-/- and FGFR3 Y367C/+ strains.Welcome to contact our team for inquiries!